IS6162A - Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður - Google Patents

Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður

Info

Publication number
IS6162A
IS6162A IS6162A IS6162A IS6162A IS 6162 A IS6162 A IS 6162A IS 6162 A IS6162 A IS 6162A IS 6162 A IS6162 A IS 6162A IS 6162 A IS6162 A IS 6162A
Authority
IS
Iceland
Prior art keywords
amyloid
clustering
inhibiting
proteins
image
Prior art date
Application number
IS6162A
Other languages
English (en)
Inventor
Elizabeth Auhelli-Szafran Corinne
Lai Yingjie
Theresa Sakkab Annette
Craswell Walker Lary
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS6162A publication Critical patent/IS6162A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS6162A 1999-06-10 2001-11-15 Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður IS6162A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13854399P 1999-06-10 1999-06-10
PCT/US2000/015073 WO2000076969A1 (en) 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (1)

Publication Number Publication Date
IS6162A true IS6162A (is) 2001-11-15

Family

ID=22482508

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6162A IS6162A (is) 1999-06-10 2001-11-15 Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður

Country Status (38)

Country Link
EP (1) EP1192131B1 (is)
JP (1) JP2003502313A (is)
KR (1) KR20020012266A (is)
CN (1) CN1156445C (is)
AP (1) AP1398A (is)
AT (1) ATE272623T1 (is)
AU (1) AU777747B2 (is)
BG (1) BG106291A (is)
BR (1) BR0011446A (is)
CA (1) CA2373394A1 (is)
CR (1) CR6530A (is)
CZ (1) CZ20014366A3 (is)
DE (1) DE60012742T2 (is)
DK (1) DK1192131T3 (is)
DZ (1) DZ3262A1 (is)
EA (1) EA004405B1 (is)
EE (1) EE200100666A (is)
ES (1) ES2223531T3 (is)
GE (1) GEP20043407B (is)
HK (1) HK1046283B (is)
HR (1) HRP20020027A2 (is)
HU (1) HUP0201586A2 (is)
IL (1) IL146455A0 (is)
IS (1) IS6162A (is)
MA (1) MA26807A1 (is)
MX (1) MXPA01011112A (is)
NO (1) NO20015992L (is)
NZ (1) NZ515619A (is)
OA (1) OA11958A (is)
PL (1) PL352294A1 (is)
PT (1) PT1192131E (is)
SI (1) SI1192131T1 (is)
SK (1) SK17622001A3 (is)
TR (1) TR200200257T2 (is)
UA (1) UA64842C2 (is)
WO (1) WO2000076969A1 (is)
YU (1) YU86801A (is)
ZA (1) ZA200109164B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
WO2000076489A2 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
JP5292300B2 (ja) * 2006-11-24 2013-09-18 エーシー イミューン ソシエテ アノニム 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのn−(メチル)−1h−ピラゾール−3−アミン誘導体、n−(メチル)−ピリジン−2−アミン誘導体、およびn−(メチル)−トリゾール−2−アミン誘導体
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
RU2531915C2 (ru) * 2008-06-09 2014-10-27 Людвиг-Максимилианс-Универзитет Мюнхен Новые лекарственные средства для ингибирования агрегации белков, вовлеченных в заболевания, связанные с агрегацией белков, и нейродегенеративные заболевания
EP2393804B1 (en) 2009-02-06 2014-04-16 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
US8835482B2 (en) * 2009-05-07 2014-09-16 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
US8946266B2 (en) 2009-07-15 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
CN102906083A (zh) 2010-01-15 2013-01-30 杨森制药公司 作为γ分泌酶调节剂的新的取代的三唑衍生物
JP2014508794A (ja) 2011-03-24 2014-04-10 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ−セクレターゼ調節剤としての新規な置換トリアゾリルピペラジンおよびトリアゾリルピペラジン誘導体
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ,インコーポレーテッド (特に)アルツハイマー病の治療に有用な置換3,4−ジヒドロ−2H−ピリド[1,2−a]ピラジン−1,6−ジオン誘導体
CN104918938B (zh) 2012-12-20 2017-08-15 詹森药业有限公司 新颖的作为γ分泌酶调节剂的三环3,4‑二氢‑2H‑吡啶并[1,2‑a]吡嗪‑1,6‑二酮衍生物
EP2945944B1 (en) 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
KR20160134865A (ko) * 2014-04-14 2016-11-23 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용
BR112017004136B1 (pt) 2014-08-29 2022-05-03 Chdi Foundation, Inc Agente de imagemamento, seu uso e compostos
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN110225753B (zh) * 2017-01-28 2022-12-09 金凯(辽宁)生命科技股份有限公司 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP2024529298A (ja) 2021-07-09 2024-08-06 プレキシウム インコーポレイテッド Ikzf2を調節するアリール化合物及び医薬組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide

Also Published As

Publication number Publication date
CN1355790A (zh) 2002-06-26
EE200100666A (et) 2003-02-17
MA26807A1 (fr) 2004-12-20
PT1192131E (pt) 2004-11-30
NO20015992L (no) 2002-02-06
SK17622001A3 (sk) 2003-06-03
WO2000076969A1 (en) 2000-12-21
CR6530A (es) 2004-03-24
HUP0201586A2 (en) 2002-08-28
HK1046283B (zh) 2005-01-07
NZ515619A (en) 2003-05-30
PL352294A1 (en) 2003-08-11
MXPA01011112A (es) 2002-06-04
EP1192131B1 (en) 2004-08-04
DK1192131T3 (da) 2004-12-13
AU777747B2 (en) 2004-10-28
KR20020012266A (ko) 2002-02-15
YU86801A (sh) 2004-07-15
AP2002002389A0 (en) 2002-03-31
JP2003502313A (ja) 2003-01-21
IL146455A0 (en) 2002-07-25
DE60012742D1 (de) 2004-09-09
UA64842C2 (uk) 2004-03-15
CA2373394A1 (en) 2000-12-21
HRP20020027A2 (en) 2005-02-28
OA11958A (en) 2006-04-13
ES2223531T3 (es) 2005-03-01
EA200101133A1 (ru) 2002-06-27
DZ3262A1 (fr) 2000-12-12
HK1046283A1 (en) 2003-01-03
TR200200257T2 (tr) 2002-06-21
GEP20043407B (en) 2004-05-10
DE60012742T2 (de) 2005-01-13
AU5312000A (en) 2001-01-02
BG106291A (bg) 2002-05-31
BR0011446A (pt) 2002-03-19
ZA200109164B (en) 2003-02-06
CZ20014366A3 (cs) 2002-11-13
EA004405B1 (ru) 2004-04-29
ATE272623T1 (de) 2004-08-15
AP1398A (en) 2005-04-21
CN1156445C (zh) 2004-07-07
EP1192131A1 (en) 2002-04-03
NO20015992D0 (no) 2001-12-07
SI1192131T1 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
IS6162A (is) Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður
DK1130989T3 (da) Fremgangsmåde og indretning til udtrækning af indholdet af en kapsel
DK1271537T3 (da) Fremgangsmåde og indretning til simplificering af adgangen til metadata
DK1177694T3 (da) Fremgangsmåde og system til levering af gps-
NO20015179D0 (no) Anordning og fremgangsmåte for venturispyling
DE69932862D1 (de) Bildaufzeichnungsgerät und -verfahren
DK1226434T3 (da) Systemer og fremgangsmåder til udförelse af magnetiske kromatografianalyser
AU2001291073A1 (en) Methods and apparatus for clock management based on environmental conditions
DE60015860D1 (de) Taktrückgewinnungsschaltung und Verfahren zur Phasendetektion
DK1698100T3 (da) System og fremgangsmåde til dannelse af et digitalt certifikat
NO20002908D0 (no) Anordning og fremgangsmÕte for borehullsundersøkelser
DE60220300D1 (de) Schaltung zur detektion eines taktsignalverlusts und verfahren dazu
DK1395987T3 (da) Indretning og fremgangsmåde til at optage information
NO20000900D0 (no) System og metode for ekstrahering av olje
IS6193A (is) Aðferð til að tálma þyrpingu amyloið protína og til að fá mynd af útfellingum þeirra
NO20055759D0 (no) Fremgangsmate og system for nedihullsklokke
FR2872355B1 (fr) Circuit integre et procede pour generer un signal d'horloge
DE60035731D1 (de) Vorrichtung zur Taktrückgewinnung
NO20000188D0 (no) Fremgangsmåte og anordning for sidebroenntilknytning
DE60027629D1 (de) Magnetaufzeichnungsgerät und -methode
DK1453356T3 (da) Fremgangsmåde til indstilling af et høresystem og et tilsvarende høresystem
DK1219175T3 (da) Fremgangsmåde til detektion og fjernelse af ikke-aftagne skalrester på skalfisk og et apparat til udövelse af fremgangsmåden
DE60031742D1 (de) Schaltung und Verfahren zur Steuerung eines Taktsignals und synchrone Verzögerungsschaltung
NO20035392L (no) Digital peilemodul og fremgangsmate for detektering
NO20011195L (no) System og fremgangsmate for raffinormalinger